our Steph, It's here.
On Slide third I Thank thank overview for everybody, X, appreciate just and a nice joining the able it. be brief agenda. today. about quarter you, to of results you, talk to
during a So of out some on we'll the recap recent we'll last calendar Immunovant quarter. bit a coming spend little and then time the talk data about year, of
Some today. catalysts time upcoming We'll to should of relatively some proof-of-concept highlight it brepocitinib talking then update VTAMA. I'll turn presentation of be at upcoming a and It review do short over about a performance financial the and Q&A. in NIU. a readout
we filing will an we'll that this an atopic want during hope our go filing III hope So in off and very commercialize that of for remind setting will a coming time just go positive continue year, that Slide everybody we even and studies, a victory on us Phase with we're amount VTAMA we shortly. of approval later we year NDA up of, lap hope and NDA year, we've will to come talked be develop we to about I in maybe last data importantly, X, take fair the this the last more which forward. following both dermatitis But both
quarter. familiar quite anti-TLXA that of the to all which culminating in the point, full sale antibody, round you're with sort of during at trip have Roche this our this We closed
point, human anti-FcRn at or a suppresses and from as we've II IMVT-XXXX, that as impact generated any convenient meaningfully initial on data our also, this without call. next-generation believe IgG, shown showing in deep we and proof-of-concept in We any say, our antibody both other from this talk that data format. data Graves' LDL study our more on subcu And exceeded Phase expectations. We'll albumin about that disease
or well. brepocitinib, to out SLE brepocitinib we've in discontinued it read so looking data our and readouts the primary forward as and quarter indication did this we finally, our development that meet from And Unfortunately, multiple in programs endpoint, bar TYKX/JAKX not additional to come. are
late-stage proud this I model earlier thing a our important programs looking really in that clinical little matters X, built bit is talked about of this year. sort a R&D readouts think of last I And and a a global pharma of including the the period, that's perfect record obviously at of comparison. possible. companies, largest look they my this -- we're patients presentation efficient is here, the track But manner on think as a one you not I over in develop as list although expense number is back our to if had Slide JPMorgan year, for to data
amount position. we our and efficiency to generated, this strong continue in with we of magnitude, develop we are extent to the being stand model and bring which the of in very we do cost, data order generally at out capital which lower, lower them, which of to just to we're capital programs on and gets of excited given list at the obviously significantly a all, we And for proud included that
data clinical about It's is on us foremost, X for and anti-FcRn strategic our really maybe updates about growth expansion. for and first XXXX delivering Slide franchise. and
already yesterday. with fiscal program development of looking some starting in short, for are year. the franchise that potentially X at in we're laying next Immunovant X updates making to programs provided couple expansive the We In years, next registrational aggressive an XX out progress indications over
us something So we fully the anti-FcRn to best-in-class think, that, that we realize of antibody. think will help potentially value
XXXX. clinical We about we expect a to it because pipeline program that a all, half opportunities, underappreciated that's advance haven't namilumab in-licensed development the range for second brepocitinib, at talked underappreciated program a and of of including in we
launch We continue the sNDA accelerate expect dermatitis. VTAMA atopic looking for to atopic forward are file revenue really to We hope in dermatitis. and we our shortly to in growth to ahead, psoriasis,
program. potential the to the has think to change continue the I trajectory of
there's the in best We that one are looking probably development, focus seen ever this point. the some next and of lot environment pipeline transformative sort on we of actively know areas. opportunities business is call stage I'll a have late-stage at mid- for development expansion to just we This of
specific expect allocation on will, I various And today. can't opportunities to excited we be that to say and in I enormously programs here across when exactly We the am near to able to strategy hands term some at of the finalize significant our then we have relatively but don't an eyes our potentially provide share and on. updates. our update capital things have we
crystallize as the be short, is form Roche, end. And we use for amount work When patients cash expect through. able reminder, consolidated yes, a previous future, with expect as Slide billion last makes to for to maximum sense. forward and be earnings time balance, expanding patients options will things capitalized we shareholders to a we think To that we're did I to an that calling And in asked which we'll Roivant's plan. a things call that it slide. meaningful as and mentioned near in pipeline, And then to we're looking that is on capital ensuring to as patient the think our an this through We sorted profitability, the return X to of X. $X.X I be end, you the on we now we to this our continuing with to in us, we allocating little updates on here provide the deal best for for in what all coming on
Slide about I've It It providing this very the few bit includes our we late-stage X, are of year. including On a batoclimab brepocitinib including definitely undisclosed a later a excited we in more Phase about program a mentioned IMVT-XXXX, here talk namilumab. II that program. little as times that we with and be that will will also on and number detail that includes including reminder, drugs VTAMA, drugs FcRn franchise [indiscernible] today,
for MDS to world to we patients. in the RVT-XXXX, want want told to modulator upfront. transfusion-dependent were low-risk data generate highlight We some I in SFXBX going that develop anemia report I our or that, to the in so of discontinue that development for interim and that data after Phase progressing, analysis our bar we've unfortunately, I/II of data. decided generated an did study not RVT-XXXX meet our
color in spent to way so on million making and it. double-digit want the those We Happy low be reasonable and we're efficient dollar scientifically, trying the sometimes don't program, you on more modest share to work I sum a these just out some decisions. things think
to focused range of development across exciting Immunovant. now up on want program options. that sets mentioned for maximum there broad strategic are strategy the I an I the to So before, turn we very value
think deep think the about lowering, batoclimab. to deep goes injection we on designed we out simple very As next-generation offers competition excited are which subcutaneous minimal are anti-FcRn there, albumin matter LDL, formulated or antibody reminder, IgG IMVT-XXXX, PTEs no to XXXX. as a similar with effect on self-administration antibody a enable as for aware with analyte basis, profile, life and of, excluding with a until that not any auto-injector patent with that hopefully we We clean a
So exciting drug. tremendously a
XX of That's and deeper against Slide evidence IgG yields across suppression, indications. a growing clinical of general, the that backdrop variety on better benefit in continued
study, have at a includes level we study, in that patient As from Graves our in which that our IgG data fully both includes available made greater data showing improvements. declines those MG-ADL better myasthenia gravis, and That not. which individual the patients, had with PET reminder, we've the
earlier milligrams both UCB, the ITP saw of we we by of with greater to IMVT-XXXX. correlated platelet efficacy Janssen milligrams studies, higher in data And those responses. XXX greater our In reduction RA correlated significantly batoclimab RA in reduction, IgG to dose, able J&J's out year, data, generated IgG data In which yielding of this put see autoantibody turn reduction, the clinical greater better showed responses. greater greater they XXX were at equivalent with
it has the drug our profile that to. that clinical privileged very appears feel we So
deep IgG as LDL. We And As with on right-hand with subcutaneous X Slide believe or impact, XXX-milligram indeed over dosing third at IgG a will X coming percent sort to XXX time the both long the feels and showing you on from ago, show in this can dosing. doses XXX-milligram suppress in like no full data data albumin charts a of see although the fiscal us milligrams. and this XX-plus on clean, effectively length was XX, that on we based data that our again quarter for generated it the suppression reminder, we
and That came dose-dependent and a together with problematic. particularly adverse not with nothing stands reminder, events on Slide clean that particularly as XX safety out profile as limited a
So date. across arm on TEAEs reported to profile a clean those severe any
So we're with that. pleased
Phase lot excited data we're not I because, we've We've we are just this want to out, about opportunity. said anybody's Graves everybody's But a as on data II II the data is Phase in spend And minute pointed then Graves a disease. talking about FcRn.
any disease to stable Graves hormone the visits, dosing all [indiscernible] then hyperthyroid see were and and prior can the milligrams ATD involves had uncontrolled of design weeks are And thyroid are XX reminder, active XXX dose You despite weeks of of at XXX stable on ATVs. Slide lower being prior on high who to dose. that dosing as with on the levels trial of the dose screening these XX drugs at who the of a patients milligrams, XX,
patients achieved dose our we remember bar ideally on exceeded believe we've you we And think we for that we but normalization versus publicly their dose respond. Slide and primary not that who the sets XX, we patients rate, was week wanted with ATD meaningfully had with up be given unique the compared And study higher lower And ATD XX only about baseline of XX, of numerically discontinuation with lower first-in-class well that was the on to and and XX primary in we that said said profile. disease, was ATD patients is disease thyroid hormones which the responses in what dose, really endpoint at higher can the XX% for dose. sort of doses best-in-class us response Graves Graves to the in tapering that that potentially
was that that We greater approaching XX% XXX-milligram meaningfully and suppressions at intend to of where as overall a development continue to running study proof here XXXX. IMVT-XXXX, expected. was said up development were will with than announce of demonstrate significant plans as mean the deep batoclimab, dose And IgG from at XXX this to we've concept we year with the we for XX%, with it to we along strategy pivot really the a
come be first. as to we out to analysis continue as more we ourselves continue opportunity to frankly, build on to So and set that our up
strategy, FcRn is on unique other intensity is of opportunity tremendous XX, the any cuts are set places basically thing indications mechanisms. development various indication, relative XX the be where of might currently any about the that is competitive from and reminder, across a there positioning mechanisms, some during we class, now but almost across disease is across see these other As such get for couple low, maximizing Slide to full to a here, We the intensity mechanism set other that for no individual anti-FcRn breadth indications surprisingly a in development there that in me questions And competitive competitive class. of broad remarkable the announced states. specific
So on more to year. said, as this I XXXX come
the We expect the potentially some side the strategic side. both continued on and unveils development -- big on on definitely
to over of and the coming continuing those looking months. provide updates course forward the So stay to tuned
on everybody orphan pipeline, rheumatology. are Lastly forward strategy just remind in latest really clinical the we our development want brepocitinib, that on oral I to pushing
extensions. year, are an to a uveitis, -- indication continue I'll registrational indications, single HS, lot And more long including as study next other as drug we term to also going as of We a of enrolling which our noninfectious coming, has that in focused out this a proof-of-concept will has IP about gotten on obviously in what year. we is in quite and protection talk this reminder, at nicely, today second, dermatomyositis as attention hope data evaluate least possible that be read and inclusive will patent this XXXX, out a well
these just here noninfectious blindness proof-of-concept of more there's living or are uveitis noninterior It's to pain, in year, remind really of approved are the -- one quite see with on U.S. unmet new Most XX. we XX,XXX inflammatory attributed soon XX,XXX each patients only of and number to on vision. to This the diseases everybody generate And the that common symptoms and data Slide therapy. in eve redness the of only There sensitivity are expect debilitating. with is patients the need given NIU cases is orphan want we floaters an important I on one that legal HUMIRA, who progressing. there's NIU
from that IL-XX And milligrams, dose. randomized specifically placebo-controlled, demonstrated what it expect and not favor is relevance trial X-dose we on have, JAKX of we based clearly between then the XX study and are evidence also have XX on a of filgotinib study are we TYKX of blinded from a pathobiology. XX. and XX, Our XX-milligram involved and that in mediated evidence Slide which by but -- design in the It's the inhibition including
it So think success than XX-milligram sort a basically and which the about treatment here, no is we're criteria set greater as rate XX%, optimistic sort sort if failure you of of a we've the of placebo we placebo, mechanism what level, first enrollment -- looking and patients, Obviously, this data arm a we'll The an be of the is of virtual small we've be the about on complete. in patient study. as quarter would said, XXXX. the we'll this expect in bar individual calendar be it, number ongoing I an data given of sharing think is at of
forward that getting data looking near we're So future. in the to
So is part I at over which to want of our underappreciated this story, another point, to turn VTAMA. quickly
We in script psoriasis. see continue growth reasonable to
and best-selling remain to You can excited see topical our We that beginning continue to the as see psoriasis, we it very we of branded on been launch, the Slide have XX. in since develop. growth are
over now We've doctors. XX,XXX written prescriptions XXX,XXX over had by
grow to continues for up net quarter. revenue revenue million product We're reasonably Our in nicely. to $XX.X the
at net has trend coverage hoping of next speaking, that to the roughly payer covered And slowly, we XXX will good gross very we continue accreting yield been that million over expect, and now Our were the for. coverage over commercial year. lives we're sort with XX%
on opportunity dermatitis the to Turning big atopic next here in Slide XX.
some study, and data seen, we data XX% at which a us, As showed from over only our head from a in in ADORING is you out atopic the study line, view XX% may extension here X with of frankly, a of improvement efficacy pretty these study, overall EASI-XX not that in just but have IGA remarkable the frankly, recently, we clear, long-term perspective, in read our puts an XX-week data, the score dermatitis. some therapies great pack of systemic the topical populations. And
is a think of moderate support with So profile events. a discontinuation low and we to continue what in have notably really set clean that of due to mild tremendous safety to here sort data a a AEs, and opportunity nothing to AD, continues very really remarkable adverse rate big
close pack and We from to perspective, expect, think and dermatitis dermatitis vast some we competitors. majority of dermatitis filed large the of them prescriptions will and tolerability XXX,XXX said, from with the of and market, sNDA as that week, needs that profile as atopic we I It set this head for an opportunity, again, shortly, written up said in to an growing year. later for is to every a a atopic a atopic our with with field the be sort potential and further the drug us safety a approval differentiates efficacy topical of with corticosteroids overall think, shape VTAMA real at the that
our next hopefully, script will So sales a year, dermatitis. and have a really exciting data quarter opportunity. notably, volume And atopic of we in some fiscal on
that sort getting there population. to the out full looking of breadth forward really in So patient of
on talked opportunities of notably we've here, NIU, of we talked data Rounding data, of to XX. year some year, clinical deeper in have Obviously, about Slide this interesting about We've in upcoming some FcRn establishing a Same the in thing out to the but coming. the gravis, lot batoclimab Phase develop IIb help IgG Phase more our in we're diseases. data we start myasthenia CIDP subcu mattering we some we're suppression, sarcoidosis, expect to potentially where going this should III is that readout with to up but data including which to think think namilumab, value gets us going begin in for today, simple a of event data has again it the that real setting that attributed anti-GM-CSF important to we but indication. first this be antibody And at getting then potential of get program the III end year Phase from successful data our the also the in year, to no potential, data. to very program
Slide net of the revenue quarter million, about million. On the of million the of financials revenues of million, or $XXX $XXX of million, $XX.X adjusted R&D $XXX SG&A expense product $XX.X about on net for about of about $XXX adjusted non-GAAP XX, million. including
$X.X something of $X.X deal, about. year, excited we're a the the net And to closing be that in billion which the the to cash a end near I Roche with the again, leaving cash know very number report don't obviously income able and is as us of position related billion, I'll equivalents of future, of of
we're haven't set continue and yet. we publicly flash come and excited quite out So close that up more to but we have a to I'll with [indiscernible] XX, that of talk as that, about Slide held rich build coming, of our and to more just to note by pipeline about parts catalysts
will Q&A. for operator you here. will will wrap the it over I to presentation thank for listening. the And I everybody that, I with turn So up
